• Opinion
• [Reporter’s View] Introducing shingles vaccines into NIP
• by Eo, Yun-Ho Apr 26, 2024 05:47am

• Company
• Forxiga prescriptions 'drop' after a 'withdrawal notice'
• by Kim, Jin-Gu Apr 25, 2024 05:50am

• Company
• Godex’s sales slow down due to various regulatory measures
• by Chon, Seung-Hyun Apr 25, 2024 05:50am

• Company
• Lipitor’s sales stay strong for good reason
• by Son, Hyung-Min Apr 25, 2024 05:50am

• Company
• Possible reimb expansion for 2nd-gen BTK inhibitor Brukinsa
• by Eo, Yun-Ho Apr 25, 2024 05:50am

• Company
• 19 K-biosimilar products sold in 11 markets after 12 yrs
• by Chon, Seung-Hyun Apr 25, 2024 05:49am

• Product
• Will Prolia be able to continue on its high growth in KOR?
• by Moon, sung-ho Apr 24, 2024 05:45am

• Opinion
• [Reporter’s View] Decreased vaccine funding during endemic
• by Son, Hyung-Min Apr 24, 2024 05:44am

• Company
• Samsung Bioepis’ Stelara biosimilar is approved in Europe
• by Chon, Seung-Hyun Apr 24, 2024 05:44am

• Company
• Prostate cancer drug Pluvicto’s approval imminent in Korea
• by Eo, Yun-Ho Apr 24, 2024 05:44am